Spruce Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRB research report →
Range $104 – $160
Price Chart
About the company
Spruce Biosciences, Inc. , founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions.
- CEO
- Javier Szwarcberg
- IPO
- 2020
- Employees
- 22
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on SPRB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $109.21M
- P/E
- -1.16
- Fwd P/E
- 10.26
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 1.72
- EV/EBITDA
- -0.59
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -118.22%
- ROIC
- -81.95%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-36,513,000
- Net Income
- $-38,966,000+26.5%
- EPS
- $-50.83+47.5%
- OCF Growth
- +40.4%
- FCF Growth
- +40.4%
- 52W High
- $112.26
- 52W Low
- $38.00
- 50D MA
- $45.96
- 200D MA
- $53.29
- Beta
- 3.54
- RSI (14)
- 37
- Avg Volume
- 88.62K
No earnings-call transcripts are available for SPRB yet.
- Free Float
- 70.0%
- Shares Outstanding
- 2.87M
- Float Shares
- 2.01M
of shares held by institutions
65 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aigh Capital Management LLC | 250.00K | 0 |
| Orbimed Advisors LLC | 200.00K | ▲ 200.00K |
| Blackrock, Inc. | 192.01K | ▲ 4.18K |
| Millennium Management LLC | 160.98K | ▲ 49.09K |
| Ikarian Capital, LLC | 121.36K | 0 |
| Vanguard Capital Management LLC | 119.33K | 0 |
| Alyeska Investment Group, L.P. | 81.67K | ▲ 30.00K |
| Adar1 Capital Management, LLC | 67.72K | ▲ 9.12K |
| Geode Capital Management, LLC | 66.76K | ▼ 3.79K |
| Cable Car Capital, LP | 60.00K | ▲ 60.00K |
| State Street Corp | 59.03K | ▲ 8.58K |
| Citadel Advisors LLC | 51.91K | ▼ 18.09K |
Held by 92 ETFs
Biggest fund positions in SPRB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 27, 26 | Quartel Adrian W | other | 13,000 |
| Jul 27, 26 | Quartel Adrian W | other | 0 |
| Jun 30, 26 | Szwarcberg Javier B. | other | 266 |
| May 21, 26 | SPIEGELMAN DANIEL K | other | 1,700 |
| May 21, 26 | SIMPSON CAMILLA V | other | 1,700 |
| May 21, 26 | GREY MICHAEL G | other | 1,700 |
| May 21, 26 | Barretto-Ko Percival | other | 1,700 |
| May 21, 26 | Walbert Keli | other | 1,700 |
| Mar 9, 26 | Hooks Corwin Dale | other | 11,000 |
| Mar 9, 26 | Hooks Corwin Dale | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SPRB coverage
Recent articles, reports, and earnings notes.
No research on SPRB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPRB report →Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company
prnewswire.com · Nov 17
Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
businesswire.com · Nov 9
Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences
businesswire.com · Nov 9
Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
businesswire.com · Nov 2
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
businesswire.com · Oct 15
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
businesswire.com · Oct 8
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
businesswire.com · Sep 8
Spruce Biosciences Announces Launch of MPS3BStudy.com
gurufocus.com · Aug 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.